help button home button Endocrine Society JCEM JCEM Call for Nominations for EIC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Monder, C.
Right arrow Articles by Lakshmi, V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Monder, C.
Right arrow Articles by Lakshmi, V.

Journal of Clinical Endocrinology & Metabolism, Vol 63, 550-557, Copyright © 1986 by Endocrine Society


ARTICLES

The syndrome of apparent mineralocorticoid excess: its association with 11 beta-dehydrogenase and 5 beta-reductase deficiency and some consequences for corticosteroid metabolism

C Monder, CH Shackleton, HL Bradlow, MI New, E Stoner, F Iohan and V Lakshmi

We describe the metabolism of cortisol (F) in three children, two of them siblings, with apparent mineralocorticoid excess (AME). As with prior patients with AME, oxidation of F to cortisone (E) was impaired, but reduction of E to F was not. We propose that this metabolic defect is caused by deficient 11-dehydrogenase associated with unimpaired 11- reductase. The following supporting observations were made: urinary C21 11-hydroxy metabolites exceeded C21 11-oxo metabolites: ratio of urinary cortols to cortolones, 6.6 +/- 2.8 (+/- SD; normal, 0.47); tetrahydrocortisol (THF) and alloTHF to tetrahydrocortisone, 14.6 +/- 5.6 (normal, approximately 1); normal subjects oxidized [11 alpha-3H]F with transfer of 3H to water; the patients did not; 11-hydroxy, but not 11-oxo, C19 steroids were excreted into the urine; and fibroblasts from patients had 5 times more 11-reductase activity than normal subjects, though fibroblasts from neither group had 11-dehydrogenase activity. Other defects of cortisol metabolism not directly associated with 11- dehydrogenase deficiency were found: impaired conversion of tetrahydro to hexahydro neutral steroids, indicating defective reductive metabolism of the side chain; depressed F production rate and increased half-life of circulating F, resulting in normal blood levels of F; increased excretion of unconjugated F metabolites; and decreased excretion of THF relative to alloTHF, consistent with a 5 beta- reductase defect. Excretion of acidic metabolites of F (cortoic acids) was within the normal range. However, little or no 20 beta-hydroxy acids were excreted, while the level of urinary 20 alpha-hydroxy acids was increased. The 11-hydroxy to 11-oxo ratio of acid metabolites was similar to values in normal subjects. The proportion of cortoic acids relative to neutral hexahydro metabolites was increased (0.37 to 1.27 in patients; 22 in normal subjects). We conclude that children with AME have multiple defects in the conversion of F to neutral metabolites, while metabolism to cortoic acids was less extensively affected. How the defects in cortisol metabolism and the symptoms of AME are related remains to be determined.


This article has been cited by other articles:


Home page
J. Am. Soc. Nephrol.Home page
M. A. Bailey, J. M. Paterson, P. W.F. Hadoke, N. Wrobel, C. O.C. Bellamy, D. G. Brownstein, J. R. Seckl, and J. J. Mullins
A Switch in the Mechanism of Hypertension in the Syndrome of Apparent Mineralocorticoid Excess
J. Am. Soc. Nephrol., January 1, 2008; 19(1): 47 - 58.
[Full Text] [PDF]


Home page
Eur J EndocrinolHome page
M. Quinkler, D. Zehnder, J. Lepenies, M. D Petrelli, J. S Moore, S. V Hughes, P. Cockwell, M. Hewison, and P. M Stewart
Expression of renal 11{beta}-hydroxysteroid dehydrogenase type 2 is decreased in patients with impaired renal function
Eur. J. Endocrinol., August 1, 2005; 153(2): 291 - 299.
[Abstract] [Full Text] [PDF]


Home page
J EndocrinolHome page
N. Draper and P. M Stewart
11{beta}-Hydroxysteroid dehydrogenase and the pre-receptor regulation of corticosteroid hormone action
J. Endocrinol., August 1, 2005; 186(2): 251 - 271.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
M. Quinkler and P. M. Stewart
Hypertension and the Cortisol-Cortisone Shuttle
J. Clin. Endocrinol. Metab., June 1, 2003; 88(6): 2384 - 2392.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
A. Odermatt, B. Dick, P. Arnold, T. Zaehner, V. Plueschke, M. N. Deregibus, H. Repetto, B. M. Frey, F. J. Frey, and P. Ferrari
A Mutation in the Cofactor-Binding Domain of 11{beta}-Hydroxysteroid Dehydrogenase Type 2 Associated with Mineralocorticoid Hypertension
J. Clin. Endocrinol. Metab., March 1, 2001; 86(3): 1247 - 1252.
[Abstract] [Full Text]


Home page
Proc. Natl. Acad. Sci. USAHome page
M. I. New and R. C. Wilson
Steroid disorders in children: Congenital adrenal hyperplasia and apparent mineralocorticoid excess
PNAS, October 26, 1999; 96(22): 12790 - 12797.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
E. Lovati, P. Ferrari, B. Dick, K. Jostarndt, B. M. Frey, F. J. Frey, U. Schorr, and A. M. Sharma
Molecular Basis of Human Salt Sensitivity: The Role of the 11{beta}-Hydroxysteroid Dehydrogenase Type 2
J. Clin. Endocrinol. Metab., October 1, 1999; 84(10): 3745 - 3749.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
G. Morineau, J.-M. Marc, A. Boudi, H. Galons, M. Gourmelen, P. Corvol, L. Pascoe, and J. Fiet
Genetic, Biochemical, and Clinical Studies of Patients With A328V or R213C Mutations in 11{beta}HSD2 Causing Apparent Mineralocorticoid Excess
Hypertension, September 1, 1999; 34(3): 435 - 441.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
R. C. Wilson, S. Dave-Sharma, J.-Q. Wei, V. R. Obeyesekere, K. Li, P. Ferrari, Z. S. Krozowski, C. H. L. Shackleton, L. Bradlow, T. Wiens, et al.
A genetic defect resulting in mild low-renin hypertension
PNAS, August 18, 1998; 95(17): 10200 - 10205.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
S. Dave-Sharma, R. C. Wilson, M. D. Harbison, R. Newfield, M. R. Azar, Z. S. Krozowski, J. W. Funder, C. H. L. Shackleton, H. L. Bradlow, J.-Q. Wei, et al.
Examination of Genotype and Phenotype Relationships in 14 Patients with Apparent Mineralocorticoid Excess
J. Clin. Endocrinol. Metab., July 1, 1998; 83(7): 2244 - 2254.
[Abstract] [Full Text]


Home page
Cardiovasc ResHome page
S. H.M. van Uum, A. R.M.M. Hermus, P. Smits, T. Thien, and J. W.M. Lenders
The role of 11{beta}-hydroxysteroid dehydrogenase in the pathogenesis of hypertension
Cardiovasc Res, April 1, 1998; 38(1): 16 - 24.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
D. J. Morris, Y. H. Lo, W. R. Lichtfield, and G. H. Williams
Impact of Dietary Na+ on Glycyrrhetinic Acid-Like Factors (Kidney 11{beta}-(HSD2)-GALFs) in Human Essential Hypertension
Hypertension, January 1, 1998; 31(1): 469 - 472.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
P. C. White, T. Mune, and A. K. Agarwal
11{beta}-Hydroxysteroid Dehydrogenase and the Syndrome of Apparent Mineralocorticoid Excess
Endocr. Rev., February 1, 1997; 18(1): 135 - 156.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1986 by The Endocrine Society